Lisanti Capital Growth LLC Has $1.36 Million Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Lisanti Capital Growth LLC grew its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 233.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,755 shares of the company's stock after purchasing an additional 40,445 shares during the quarter. Lisanti Capital Growth LLC owned about 0.06% of Dyne Therapeutics worth $1,361,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Creative Planning grew its stake in shares of Dyne Therapeutics by 41.5% in the third quarter. Creative Planning now owns 10,605 shares of the company's stock valued at $381,000 after acquiring an additional 3,111 shares in the last quarter. US Bancorp DE boosted its holdings in Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company's stock valued at $49,000 after purchasing an additional 1,212 shares during the period. Hanseatic Management Services Inc. acquired a new position in shares of Dyne Therapeutics during the 3rd quarter worth approximately $258,000. Privium Fund Management B.V. increased its holdings in shares of Dyne Therapeutics by 7.1% during the third quarter. Privium Fund Management B.V. now owns 15,016 shares of the company's stock worth $539,000 after purchasing an additional 1,000 shares during the period. Finally, State of New Jersey Common Pension Fund D acquired a new stake in shares of Dyne Therapeutics in the third quarter valued at approximately $1,588,000. Institutional investors own 96.68% of the company's stock.

Insider Buying and Selling at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the sale, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Richard William Scalzo sold 1,455 shares of the company's stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the sale, the senior vice president now directly owns 127,078 shares in the company, valued at approximately $3,573,433.36. This represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 6,387 shares of company stock worth $142,789. 20.77% of the stock is currently owned by insiders.

Remove Ads

Dyne Therapeutics Trading Up 4.6 %

NASDAQ:DYN traded up $0.53 on Tuesday, hitting $12.03. The company had a trading volume of 2,313,038 shares, compared to its average volume of 2,205,881. Dyne Therapeutics, Inc. has a 52 week low of $11.18 and a 52 week high of $47.45. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -3.38 and a beta of 1.11. The firm has a 50 day moving average of $15.56 and a two-hundred day moving average of $26.06.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. As a group, equities analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Wall Street Analysts Forecast Growth

DYN has been the topic of a number of analyst reports. Guggenheim reissued a "buy" rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Royal Bank of Canada reissued an "outperform" rating and set a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Piper Sandler dropped their price target on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Chardan Capital reaffirmed a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research report on Friday, February 28th. Finally, Baird R W raised shares of Dyne Therapeutics to a "strong-buy" rating in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $48.75.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.